GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy.

Area of Science:

• Neuroscience
• Molecular Biology
• Epilepsy Research

Background:

• Temporal lobe epilepsy (TLE) involves seizures originating in the hippocampus and often presents drug resistance.
• Aberrant networks in TLE utilize kainate receptors (KARs), specifically those containing GluK2/GluK5 subunits.
• Current treatments for TLE are insufficient, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the efficacy of downregulating KARs in the hippocampus as a gene therapy for TLE.
• To provide evidence for reducing chronic epileptic discharges in TLE by targeting GluK2 expression.

Main Methods:

• Utilized rodent models of TLE and human hippocampal slices from drug-resistant TLE patients.
• Employed molecular biology techniques and electrophysiology to assess KAR function and gene silencing.
• Developed an adeno-associated virus (AAV) serotype-9 vector expressing anti-grik2 miRNA to target GluK2 expression.

Main Results:

• A non-selective KAR antagonist reduced interictal-like epileptiform discharges (IEDs) in human TLE slices.
• AAV9-anti-grik2 miRNA delivered to TLE mice significantly decreased seizure activity.
• Transduction of human TLE slices with AAV9-anti-grik2 miRNA reduced GluK2 protein and IEDs.

Conclusions:

• Gene silencing of GluK2 expression via AAV9-anti-grik2 miRNA inhibits chronic seizures in a TLE mouse model.
• This strategy also reduces IEDs in TLE patient-derived hippocampal slices, demonstrating translational potential.
• The findings support a gene therapy approach targeting GluK2 KARs for drug-resistant TLE.